Bregal Milestone Announces the Sale of Epassi to TA Associates and Warburg Pincus
Bregal Milestone, a leading pan-European technology growth private equity firm, today announced the sale of Epassi Group (“Epassi”), a market leader in the provision of employee benefits within the Nordics, and a leading player in the UK, Ireland, and Italy, to TA Associates and Warburg Pincus LLC.
Founded in 2007 and based in Espoo, Finland, Epassi is a leading provider of mobile payment solutions for the provision of employee benefits and other services. With over 13 million users, Epassi's mobile payment solution allows employees to easily access their employee benefits, such as meal vouchers, gym memberships, and parking passes, with a single app. In addition, the Epassi app can be used to pay for goods and services at over 59,000 service providers. As one of the fastest growing Nordic companies, Epassi was named to the Financial Times’ 1000 Fastest Growing Companies in Europe in 2019, 2022 and 2023.
Since Bregal Milestone’s initial investment in 2019, Epassi has cemented its leadership position and undergone a period of accelerated growth, including:
- Increasing revenue (GMV) 9x
- Increasing net revenues 6x
- Increasing EBITDA 7x
- Completing five add-on acquisitions across Europe
- Expanding its global footprint into Sweden, the UK, Ireland, and Italy
- Recruiting key C-level leadership including CEO Pekka Rantala and CFO Regina Duzanskaj
- Optimizing sales and profitability via our in-house data analytics capabilities delivered by Bregal Milestone’s in-house value creation team, Milestone Performance Partners
- Executing ESG-positive actions which resulted in a 38% improvement in Scope 1 & 2 emissions, and an independent rating as “best practice” against KPIs for 4 key ESG focus areas - Board Oversight, Cybersecurity and Privacy policies, Social Impact actions, and Business Integrity policies and results
“Bregal Milestone has been instrumental to our growth over the past several years and we believe that the timing of passing the ownership torch is ideal. With Bregal Milestone’s help, we have successfully expanded beyond the Nordics, and outside of our core business in the provision of employee benefits. We believe that with the scalable technology we have in place, we are sufficiently prepared to continue to scale into additional geographies and adjacent business areas in our next stage of growth,” says Pekka Rantala, CEO of Epassi.
“It has been a tremendous privilege to work with Risto, Pekka, and the talented Epassi leadership team to help build enormous value for the company's passionate customers, employees, and shareholders. We are proud to have helped build one of Europe’s leading employee benefits disruptors, exponentially growing revenues and profitability since our initial investment in 2019. From day one this partnership had a relentless focus on teamwork, high performance, and excellence,” added Cyrus Shey, co-founder and Managing Partner at Bregal Milestone.
“During our ownership, our successful M&A activity helped to expand Epassi’s business into five European markets, cementing our position as one of the leading pan-European employee benefits payments providers,” said Saachi Oza, Principal at Bregal Milestone.
In addition to our M&A activity, we were pleased to have worked with Pekka to build a talented leadership team and provide stewardship and support across several areas including the Epassi go-to-market strategy, their technology evolution, operational integration, and ESG. We wish Epassi continued success in their next stage of growth,” added Rob Hetherington, Epassi Chairman, Partner, and Head of Milestone Performance Partners (Bregal Milestone’s in-house value creation team).
Terms of the transaction were not disclosed. The transaction is subject to customary closing conditions. J.P. Morgan acted as exclusive financial advisor and White & Case acted as legal counsel to Bregal Milestone and Epassi.
About Epassi
Epassi, founded in 2007 in Helsinki, is a market leader in the provision of employee benefits within the Nordics, Italy, and the UK. The unique and scalable solution drives mobile tech and payment solutions to open up a world of health and well-being possibilities, combining all benefits in one user-friendly service. Epassi Group is Europe’s leading digital solution for employee benefits, with a reach of nearly 13 million users, over 13,500 employers, and more than 59 000 service providers. Epassi is a trailblazer fintech company in the Nordic countries and has been awarded by the Financial Times as one of the fastest growing companies in Europe in 2022 and 2023.
Epassi – Boosting everyday well-being.
www.epassi.com
About Bregal Milestone
Bregal Milestone is a leading technology growth private equity firm with c.€1.3 billion of capital raised since inception. The firm provides growth capital and strategic assistance to support market-leading technology companies. Bregal Milestone is part of Bregal Investments, a leading global investment platform with over €16 billion in assets under management. For more information, visit www.bregalmilestone.com or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230809476156/en/
Contact information
Jillian Hazelton
Head of Marketing & Communications
Jillian.hazelton@bregal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP3606.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaboration, with Radial Health, Inc., a growing national network of interventional psychiatry practices leveraging technology and operations expertise to optimize models of care delivery. This collaboration will further help to inform the development of scalable delivery models for investigational COMP360 psilocybin treatment, if FDA approved. The agreement with Radial expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with mental health conditions receive their care in the United States. Radial is building a national network of clinics across the U.S., delivering interventional, evidence-based treatments for mental health conditions. The co-founders have a mission-driven background in designing customer-centric care and bui
Hitachi Launches Expanded HMAX Solutions Accelerating Social Innovation Globally Across Industries6.1.2026 12:30:00 EET | Press release
Hitachi, Ltd. (TSE:6501, "Hitachi") today introduced HMAX by Hitachi at CES 2026. HMAX by Hitachi is a suite of next-generation solutions that brings the power of AI to social infrastructure. By harnessing vast data from physical and digital assets, integrating advanced AI, and applying Hitachi’s unmatched domain expertise, HMAX tackles the most complex social infrastructure challenges—maximizing outcomes and value for our clients and society. These solutions are derived from the formalized HMAX design principles, integrating a dynamic collection of advanced technologies and a robust partner ecosystem that helps elevate end-system reliability and performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106885363/en/ HMAX by Hitachi: the suite of next-generation solutions that brings the power of AI to social infrastructure. HMAX combines data collected from physical and digital assets such as sensors, industrial equipm
Pandorum Technologies and Nucelion Therapeutics Announce Strategic Collaboration to Manufacture Exosome-Based Tissue Regenerative Therapy for Ocular Diseases in APAC Markets6.1.2026 12:00:00 EET | Press release
Pandorum Technologies, a clinical-stage regenerative medicine company building a next-generation platform for programmable tissue regeneration, today announced a strategic collaboration with Hyderabad based Nucelion Therapeutics, a specialized contract research, development and manufacturing organization (CRDMO), to expand manufacturing capabilities for Pandorum’s exosome-based therapeutic platform across the Asia-Pacific (APAC) region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106214233/en/ This strategic collaboration aligns with a shared vision, as Pandorum’s asset(s) progress toward clinical trials. By leveraging Nucelion Therapeutics’ manufacturing capabilities, the partnership supports regional supply and regulatory readiness, marking a strategic step forward. Furthermore, it reaffirms India’s growing capability to develop and manufacture cutting-edge biologic therapies for the world. “Pandorum is building a gl
KAYTUS Completes 100-Cabinet Liquid-Cooled Data Center in Europe in Four Months6.1.2026 10:02:00 EET | Press release
KAYTUS announced that it has accelerated the deployment of large-scale liquid-cooled AI data centers through its integrated turnkey service. By combining deployment and commissioning, KAYTUS delivers a one-stop, end-to-end service, from installation to optimization and launch. Recently, KAYTUS completed the delivery of a 100-cabinet, high-density liquid-cooled AI data center in Europe in just four months, up to 80% faster than traditional deployment models. Through professional performance testing and tuning, overall system performance was improved by 20%, enabling a stable, high-efficiency business launch through on-site optimization and customization. This accelerated and resilient delivery addresses urgent AI infrastructure timelines and provides a scalable blueprint for deploying high-density liquid-cooled clusters across Europe. The customer is a European infrastructure unicorn delivering compute, storage, and networking services to the e-commerce, fintech, and digital media secto
Kashiv BioSciences to Present at the 44 th Annual J.P. Morgan Healthcare Conference6.1.2026 10:00:00 EET | Press release
Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced that Dr. Sandeep Athalye, Global Chief Executive Officer, and Dr. Paras Vasanani, Head of Business Development, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 14, 2026, at 11:00 a.m. PST. 44th Annual J.P. Morgan Healthcare Conference – Kashiv BioSciences Company Presentation Date: Wednesday, January 14, 2026 Time: 11:00 - 11:25 a.m. PST Location: Golden Gate Conference Room – The Westin St. Francis Hotel, San Francisco, California About Kashiv BioSciences: Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv BioSciences, LLC in the USA, and its subsidiaries in India (together “Kashiv BioSciences”) operat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
